The KRAS G12C inhibitor field is evolving at a breakneck pace. While sotorasib set an initial benchmark response rate of ~30% (in combo), newer agents like oloramoracep are already demonstrating response rates exceeding 45%, rapidly resetting efficacy expectations and treatment standards for this population.

Previously untargetable, the KRAS G12D mutation—often found in never-smokers—is on the verge of becoming actionable. Emerging specific inhibitors like Zoldanrasib are showing high response rates (over 60%), suggesting a new targeted therapy option for a patient group that previously lacked one.

Instead of a traditional chemotherapy comparison, Divarasib's registrational study is a head-to-head trial against approved KRAS G12C inhibitors. This trial design reflects a strategic shift towards proving superiority within a new drug class, not just efficacy against older standards of care.

Unlike earlier G12C-specific "RAS-off" drugs that lock KRAS in an inactive state, new "RAS-on" inhibitors form a tri-complex with an active form of RAS and an endogenous protein. This novel mechanism enables targeting of a much broader spectrum of RAS mutations, representing a significant breakthrough for treating pancreatic cancer.

A new class of drugs, "RAS on" inhibitors (e.g., daxorarasib), targets the active, GTP-bound state of KRAS. This mechanism is distinct from first-generation "RAS off" inhibitors (e.g., sotorasib) and is designed to treat patients who develop resistance, offering a subsequent line of targeted therapy.

In frontline clinical trials for KRAS G12C NSCLC, combining olomorasib with pembrolizumab alone yielded a 90% response rate in patients with >50% PD-L1 expression. This surpassed the 78% rate seen when chemotherapy was added, suggesting a more targeted approach may be superior for this specific biomarker-defined subgroup.

The efficacy of new KRAS inhibitors is set to fundamentally shift pancreatic cancer research. These agents are expected to become the new standard therapeutic backbone, meaning future clinical trials will likely test new drugs in combination with a RAS inhibitor, moving beyond chemotherapy-only combinations.

The combination of deveracib and pembrolizumab shows remarkably high response rates (over 70%) and a promising 19.3-month median PFS in PD-L1 positive patients. This chemotherapy-free regimen demonstrates substantial activity even in PD-L1 negative patients, suggesting a potential paradigm shift away from chemotherapy for this common mutation.

In the rare scenario of colorectal cancer with both HER2 amplification and a KRAS G12C mutation, US-based experts might prioritize KRAS-directed therapy. This preference is driven by durable data for KRAS inhibitors, even though choosing between targets is difficult without direct comparative studies.